The D3 trial is open and recruiting fast!
14 Jul 2022
A new trial opened in May, aiming to find out if children and young people living with HIV can take two anti-HIV medicines instead of three. The trial has already recruited 74 participants in Uganda and Thailand.
People living with HIV have to take medicines for life. Therefore, it is important to ensure that these medicines work well and continue to be safe to take for children and young people living with HIV. New approaches that make these anti-HIV medicines less toxic and easier to take could help improve their quality of life and outcomes.
The D3 trial is testing if a new tablet that contains two anti-HIV medicines (dolutegravir and lamivudine) is safe and as effective as the currently recommended treatment (dolutegravir plus two other medicines).
The study is taking place in five countries, including South Africa, Spain, Thailand, Uganda, and the UK. The trials aims to recruit 370 children and young people living with HIV, aged between 2 and 15 years old, to take part.
Well done to the D3 sites, the MRC CTU team (Mags Thomason, Nazia Parkar, Aziza Mirza, Iona White, Anas Omar Anna Turkova, Deborah Ford, Liz James, Man Chan, Catherine Wedderburn, Anna Turkova), the Penta team and our collaborators in Radboud University, Nijmegen (Pharmacokinetic substudy) and the Advance Pathogen Diagnostic Unit at the UCLH (Virology substudy).
D3 is funded by ViiV Healthcare and sponsored by Penta. The trial is coordinated by the MRCCTU at UCL in close collaboration with Penta and PHPT CTU (Thailand).